HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Dual role of lipoxin A4 in pneumosepsis pathogenesis.

Abstract
Lipoxin A4 (LXA4) is an endogenous lipid mediator with potent anti-inflammatory actions but its role in infectious processes is not well understood. We investigated the involvement of LXA4 and its receptor FPR2/ALX in the septic inflammatory dysregulation. Pneumosepsis was induced in mice by inoculation of Klebsiella pneumoniae. LXA4 levels and FPR2/ALX expression in the infectious focus as well as the effects of treatment with receptor agonists (LXA4 and BML-111) and antagonists (BOC-2 and WRW(4)) in early (1h) and late (24h) sepsis were studied. Sepsis induced an early increase in LXA4, FPR2/ALX lung expression, local and systemic infection and inflammation, and mortality. Treatment with BOC-2 in early sepsis increased leukocyte migration to the focus, and reduced bacterial load and dissemination. Inhibition of 5- and 15-lipoxygenase in early sepsis also increased leukocyte migration. Early treatment with WRW(4) and BOC-2 improved survival. Treatment with authentic LXA4 or BML-111 in early sepsis decreased cell migration and worsened the infection. In late sepsis, treatment with BOC-2 had no effect, but LXA4 improved the survival rate by reducing the excessive inflammatory response, this effect being abolished by pretreatment with BOC-2. Thus, the anti-inflammatory and pro-resolution mediator LXA4 and its receptor FPR2/ALX levels were increased in the early phase of sepsis, contributing to the septic inflammatory dysregulation. In addition, LXA4 has a dual role in sepsis and that its beneficial or harmful effects are critically dependent on the time. Therefore, a proper interference with LXA4 system may be a new therapeutic avenue to treat sepsis.
AuthorsRegina Sordi, Octávio Menezes-de-Lima Jr, Verônica Horewicz, Karin Scheschowitsch, Laís F Santos, Jamil Assreuy
JournalInternational immunopharmacology (Int Immunopharmacol) Vol. 17 Issue 2 Pg. 283-92 (Oct 2013) ISSN: 1878-1705 [Electronic] Netherlands
PMID23816538 (Publication Type: Journal Article)
CopyrightCopyright © 2013 Elsevier B.V. All rights reserved.
Chemical References
  • 5(S),6(R)-7-trihydroxyheptanoic acid, methyl ester
  • Heptanoic Acids
  • Interleukin-1beta
  • Lipoxins
  • Oligopeptides
  • Receptors, Formyl Peptide
  • Tumor Necrosis Factor-alpha
  • formyl peptide receptor 2, mouse
  • lipoxin A4
  • tryptophyl-arginyl-tryptophyl-tryptophyl-tryptophyl-tryptophanamide
  • butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine
Topics
  • Animals
  • Bacterial Load (drug effects)
  • Cell Movement (drug effects)
  • Cells, Cultured
  • Disease Progression
  • Heptanoic Acids (administration & dosage, pharmacology)
  • Interleukin-1beta (blood)
  • Klebsiella Infections (complications, immunology)
  • Klebsiella pneumoniae (immunology)
  • Lipoxins (administration & dosage, immunology, metabolism)
  • Lung (drug effects, immunology, microbiology)
  • Male
  • Mice
  • Oligopeptides (administration & dosage, pharmacology)
  • Receptors, Formyl Peptide (agonists, antagonists & inhibitors)
  • Sepsis (etiology, immunology)
  • Tumor Necrosis Factor-alpha (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: